Trial Profile
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma
- Focus Adverse reactions
- 06 Apr 2017 New trial record